Gemini Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Gemini Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04684394
- Locations
- 🇺🇸
Gemini Clinical Trial Site 18, Winter Haven, Florida, United States
🇺🇸Gemini Clinical Trial Site 7, Pinellas Park, Florida, United States
🇺🇸Gemini Clinical Trial Site 2, Asheville, North Carolina, United States
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Gemini Therapeutics, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT04643886
- Locations
- 🇺🇸
Gemini Clinical Trial Site, Virginia Beach, Virginia, United States
First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Gemini Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04246866
- Locations
- 🇺🇸
California Retina Consultants, Santa Maria, California, United States
🇺🇸Retina Vitreous Associates, Beverly Hills, California, United States
🇺🇸Pepose Vision Institute, Chesterfield, Missouri, United States
© Copyright 2024. All Rights Reserved by MedPath